Status:
COMPLETED
Deferoxamine for the Treatment of Hemochromatosis
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Diabetes Mellitus
Heart Disease
Eligibility:
All Genders
4+ years
Brief Summary
When patients receive repeated blood transfusions the level of iron in the patient s blood can rise. When iron is processed in the body a protein known as hemosiderin can begin collecting in the organ...
Detailed Description
The purposes of this protocol are two-fold: 1) to determine whether deferoxamine, given subcutaneously on a regular basis, can indefinitely prevent the cardiac, endocrine and hepatic complications of ...
Eligibility Criteria
- INCLUSION CRITERIA
Patients studied under this protocol will be at risk for or have evidence of significant excess tissue iron.
Most patients will be on regular blood transfusion secondary to either congenital or acquired anemia.
The majority of patients have homozygous beta thalassemia.
Patients with sickle cell anemia will be included only when there is an absolute indication for regular blood transfusions (e.g., a history of stroke).
Twenty to thirty adults with acquired anemia and good long-term prognosis will be accepted for study if chelation can be initiated early in their transfusion history (less than 30-50 units).
EXCLUSION CRITERIA
Such patients will be excluded from study if they have diabetes or cardiac disease due to another cause (coronary artery or valvular heart disease).
Key Trial Info
Start Date :
April 22 1985
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2015
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT00001203
Start Date
April 22 1985
End Date
November 9 2015
Last Update
December 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892